Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15
ASH Oral Presentation Details:Event 68th ASH Annual Meeting and Exposition, New Orleans, LATitle "45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in
Immix is showing research results for a blood cancer medicine at a big doctor conference. When companies present good safety data, it can mean their medicine is on track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.